BioSpace News Archive

PathoQuest announces the closing of an 8M euros financing series.

Achieve Life Sciences, Inc. announced the Company will host its first investor day on Friday, September 20, 2019 in New York City.

Brings Traceability to Industry Growing at 7.5% CAGR1; Navarpluma to Offer SigNature® DNA to Manufacturing Customer Base

Exclusive editorial project covers the U.S., Asia, Africa and the Middle East

Centralized Application Service (CAS™) optimizes admissions process and boosts application growth, application completion rates and gender parity in student populations [05-September-2019] WATERTOWN, Mass. , Sept. 5, 2019 /PRNewswire/ -- Liaison International, the leader in admissions management and enrollment marketing solutions for higher education, today provided d

CASI Pharmaceuticals, Inc. announces it will host a key opinion leader symposium addressing innovations in cancer immunotherapy and recent regulatory reforms impacting the China biopharmaceutical market.

JSR Life Sciences Companies Selexis SA and KBI Biopharma, Inc. have announced a new collaboration with ZyVersa Therapeutics to advance development of ZyVersa’s lead inflammasome inhibitor, IC 100, for the treatment of multiple inflammatory conditions.

Can-Fite BioPharma Ltd. announced the Company’s CEO Dr. Pnina Fishman will present at the H. C. Wainwright 21st Annual Global Investment Conference to be held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City.

Aleta Biotherapeutics announced the appointments of Mark Leuchtenberger as Executive Chairman and Eva-Lotta Allan as Non-Executive Director effective immediately.

Bristol-Myers Squibb Company announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo to the current standard of care versus the standard of care alone did not meet one of its primary endpoints, progression-free survival, in patients with newly diagnosed glioblastoma multiforme that is O6-methylguanine-DNA methyltransferase-methylated.